State Doubles Down To Vaccinate Hard-To-Reach Communities oakdaleleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oakdaleleader.com Daily Mail and Mail on Sunday newspapers.
C-Path and Tufts Medical Center have announced a joint venture to integrate the first patient-level clinical trial data to generate actionable real-world evidence for neonatal drug development, from real-world neonate data. This activity, funded by the FDA, is being executed through a neonatal pilot project within C-Path s International Neonatal Consortium.
E-Mail
(Boston) Ridiane Denis, BS, RN, MD, director of clinical research and operations at BU s Clinical & Translational Science Institute, has received a 2021 Perkins Award for distinguished service to the University. Denis is one of three winners of this annual award administered by BU s Faculty Council.
In a letter nominating Denis, a colleague wrote I cannot identify a bigger hero in our research enterprise than Dr. Denis, who not only worked with multiple partners and [principal investigators] but also supported her staff through this difficult and sometimes uncertain period of time. I have witnessed the long hours, the incredible dedication, and the passion she has put into not only our project, but also the important research that Boston Medical Center (Boston University School of Medicine s teaching hospital) has carried out to improve our knowledge of this pathogen and improve care of our patients.
CFTR modulator can be safe, well-tolerated for younger children with common form of cystic fibrosis
Children ages two to five who have the most common form of cystic fibrosis (CF), caused by two copies of the F508 gene mutation, have not had any modulator treatments available to them until recently. A new study authored by researchers at Children s Hospital Colorado and published May 6, 2021, in
Lancet Respiratory Medicine shows that the CFTR modulator - lumacaftor/ivacaftor - can be safe and well-tolerated for this age range for up to 120 weeks, allowing younger children to begin proactive treatment of CF earlier in their lives.
Twitter Facebook
As BU scrambled to build a COVID-19 testing lab from the ground up last spring, its scientific director, Catherine Klapperich, tapped trusted help for an endeavor fraught with unknown safety risk: her former student and current colleague Lena Landaverde (ENG’13,’17), assistant director of the College of Engineering’s Precision Diagnostics Center.
“Since May 2020, Lena has been my equal partner” in the Charles River Campus Clinical Testing Laboratory, wrote Klapperich, an ENG professor and vice chair of biomedical engineering. “She is my hands in the lab and on the ground while I work largely virtually. She took personal risks to be in the lab [last] spring when we did not know how dangerous working with or near SARS-CoV-2 might be. Her courage, tenacity, creativity, and intellectual quickness and flexibility match or exceed anyone I have worked with at BU in 18 years.”